Pharmaceuticals Sector - Solvay

More documents

Recommendations

Info

16 Solvay Global Annual Report 2005 Three priority directions have been selected in response to these changes. Portfolio orientation: greater selectivity in order to increase our chances of success in an ever more demanding regulatory and medical environment. – “Cardiometabolic” specialties and “neuroscience” are now our main areas of therapeutic interest. We shall continue to invest in every aspect of them, from research and development (R&D) through to global marketing. We are also actively seeking licensing agreements with which to balance out and increase our coverage of this area. – Flu vaccines and pancreatic enzymes directly linked to unmet medical needs will be the subject of targeted investments, including R&D and licensing agreements. – We shall be progressively de-emphasizing research in male and female hormone treatments. These will constitute a downstream activity, concentrated on marketing and supported by licence buy-ins and acquisitions. Performance objectives: We have clearly defi ned the changes we need to make and the timetables we need to adhere to in order to achieve our 2010 objectives. Clearly specifi ed targets will enable us to develop a long-term product line which meets the needs of the medical world and of external players like the fi nancial community. A global organization: To attain these performance goals, the organization has been redefi - ned with a global vision, aimed at achieving or exceeding reference values for effi ciency and effectiveness in each functional area. The organization will be optimized to take it past the critical size threshold, whilst remaining light and fl exible in order to adapt and change faster and better than many other players. Development by individual therapeutic fi elds and geographic areas The results for the Sector include those of Fournier Pharma since August 1, 2005. Sales are up 30% on 2004. Without Fournier Pharma they would have been up 15%. These growth rates are above those of the pharmaceutical industry as a whole. The United States remains our largest market with 33% of sales. These were up by 39%, including Fournier Pharma. Apart from a handful of countries, sales in Western Europe recovered signifi cantly from 2004. In Russia they leapt forward a spectacular 80% thanks to greater geographic coverage and the introduction of a national reimbursement system. Growth was sustained in South Africa, Australia and the Middle East and in our priority development zones of Brazil and Canada. We are paying increasing attention to Asia, where our sales remain modest, but where our growth rate is high. “ Sales are up 30% on 2004.”
Cardiometabolic Cardiovascular disease remains a major world health problem as a result of contemporary lifestyles. Pharmaceutique Pharmaceuticals 17 17 Solvay Global Annual Report 2005
Page 1 and 2: Driven by the future Growth, Compet
Page 3 and 4: Highlights January 2005 Solvay fi n
Page 5 and 6: Activities Group sales 2005 = EUR 8
Page 7 and 8: Our Vision - Independent industrial
Page 9 and 10: here to stay, in our view irreversi
Page 11 and 12: Board of Directors and Corporate Go
Page 13 and 14: 4 Executive Committee and General M
Page 15 and 16: Such a strategy is possible only wi
Page 17 and 18: Specialities Solvay Specialties fro
Page 19: Key fi gures [EUR million] Pharmace
Page 23 and 24: Cardiometabolics Fenofi brate, TRIC
Page 25 and 26: “ DUODOPA® entered Solvay’s pr
Page 27 and 28: Pharmaceuticals Sector Therapeutic
Page 29 and 30: Key fi gures [EUR million] Chemical
Page 31 and 32: Growth To speed up its growth, the
Page 33 and 34: Initiatives have also been launched
Page 35 and 36: “ The ‘Soil Remediation Reagent
Page 37 and 38: Key fi gures [EUR million] Plastics
Page 39 and 40: Innovation “Twin-Sheet Blow Mould
Page 41 and 42: Plastics 37 Solvay Global Annual Re
Page 43 and 44: which it was able to take advantage
Page 45 and 46: New Business Development Priority t
Page 47 and 48: Meeting The Science Days organized
Page 49 and 50: Human Resources The Group’s fi ve
Page 51 and 52: “ At the end of this seminar, all
Page 53 and 54: Sustainable Development 2005 saw th
Page 55 and 56: Accident frequency rate Persons wor
Page 57 and 58: Management Report New records for S
Page 59 and 60: Expenditure on the future by Sector
Page 61 and 62: Financial Statements The following
Page 63 and 64: Consolidated balance sheet EUR mill
Page 65 and 66: IFRS valuation rules The main accou
Page 67 and 68: 9. Impairment Every year the Group
Page 69 and 70: Notes to the fi nancial statements
Page 71 and 72:
(2) Financial data by region These
Page 73 and 74:
and the estimated fi nancial conseq
Page 75 and 76:
The deferred taxes recorded in the
Page 77 and 78:
2005 Millions EUR Acquisitions Disp
Page 79 and 80:
Neopharma On January 19, 2005 the S
Page 81 and 82:
(around 300 persons) with a view to
Page 83 and 84:
In 2005 the impairment tests on goo
Page 85 and 86:
Solvay Group purchased 100% of the
Page 87 and 88:
Post-employment benefi t plans are
Page 89 and 90:
Actuarial assumptions used in deter
Page 91 and 92:
Analysis of total fi nancial debt b
Page 93 and 94:
In this way, at the end of 2005, th
Page 95 and 96:
The following amounts relating to J
Page 97 and 98:
PORTUGAL Fournier Farmaceutica Port
Page 99 and 100:
List of fully consolidated Group co
Page 101 and 102:
Solvay Salz Holding GmbH, Hannover
Page 103 and 104:
CANADA Fournier Pharma, Inc., Montr
Page 105 and 106:
GREAT BRITAIN Inergy Automotive Sys
Page 107 and 108:
Summary fi nancial statements of So
Page 109 and 110:
Statutory auditor’s report to the
Page 111 and 112:
The Solvay share compared with the
Page 113 and 114:
Contacts: The Investor Relations Te
Page 115 and 116:
Shareholders’ Diary - May 9, 2006
show all

Pharmaceuticals Sector - Solvay

Create successful ePaper yourself

Delete template?

Save as template?